DCVC

Activity from announced rounds

Activity in this selectionOct 27, 2026 · Sep 28, 2026

DCVC is an investment firm identified by TypeSafe AI as an existing investor and by its own communications as a backer of Shennon Biotechnologies.

Recorded funding activity

TypeSafe turns unstructured inputs into typed decisions and probability scores for automated software. Shennon develops T-cell engager therapies for solid tumors. Separate TypeSafe financings remain separate events under one investor history.

Sources
Rounds participated in
3
Confirmed lead rounds
2
All roles disclosed
New companies
2
First participation on record · 1 follow-on
Funding in participating rounds
$879.5M
2 disclosed · full round size, not this investor’s share

By stage

Series A2
Seed1

By primary sector

AI1
Hardware1
Healthtech1

By country

United States2
United Kingdom1

Rounds

3 in this selection
BioStack

BioStack builds clinical data pipelines and realistic training environments for healthcare and drug-discovery AI.

$9.5MSeed
Lead
TypeSafe AI

Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.

$870MSeries A
Participant
Universal Quantum

Modular trapped-ion quantum computers built by connecting small quantum chips.

>$100MSeries A
Lead